10-Q: BioAtla Reports Q3 2024 Results, Revenue Boosted by Licensing Deal

BioAtla, Inc. reported a net loss of $10.6 million for the third quarter of 2024, with revenue of $11 million driven by a licensing agreement.

Summary

• BioAtla, Inc. reported a net loss of $10.6 million for the three months ended September 30, 2024, compared to a net loss of $33.3 million for the same period in 2023.
• The company's revenue for the quarter was $11 million, primarily from a licensing agreement with Context Therapeutics.
• Research and development expenses decreased to $16.4 million for the quarter, down from $28.4 million in the prior year period.
• General and administrative expenses were $5.9 million, a decrease from $6.6 million in the same quarter of 2023.
• For the nine months ended September 30, 2024, the net loss was $54.9 million, compared to $96.5 million for the same period in 2023.
• The company's cash and cash equivalents totaled $56.5 million as of September 30, 2024.
• BioAtla expects its current cash and cash equivalents to fund operations for at least twelve months from the date of the financial statements.

Sentiment

Score: 6

Explanation: The document shows a positive trend in reducing losses and generating revenue, but the company still faces significant risks and challenges. The sentiment is cautiously optimistic.

Positives

• The company's net loss significantly decreased in both the three and nine month periods ending September 30, 2024 compared to the same periods in 2023.
• BioAtla generated $11 million in revenue from a licensing agreement, a new source of income for the company.
• Research and development expenses decreased due to the completion of enrollment in certain clinical trials and a focus on selected high potential indications.
• General and administrative expenses decreased due to lower stock-based compensation and D&O insurance premiums.

Negatives

• BioAtla continues to incur net losses and negative cash flows from operations.
• The company's cash and cash equivalents decreased from $111.5 million at the end of 2023 to $56.5 million as of September 30, 2024.
• Interest income decreased due to lower cash and cash equivalents compared to the same period in 2023.

Risks

• BioAtla is a clinical-stage company with a limited operating history and no products approved for commercial sale.
• The company will require substantial additional capital to finance its operations.
• Product candidates may fail in development or suffer delays that adversely affect their commercial viability.
• The market may not be receptive to the company's product candidates due to their novel therapeutic modality.
• The company faces competition from entities that have developed or may develop product candidates for cancer.
• The company may be unable to obtain U.S. or foreign regulatory approval for its product candidates.
• A portion of the company's research and development activities take place in China, which is subject to various risks.
• The company faces risks related to health epidemics and outbreaks which could significantly disrupt its preclinical studies and clinical trials.

Future Outlook

BioAtla expects its current cash and cash equivalents to be sufficient to fund its ongoing operations for a period of at least twelve months from the date of issuance of the financial statements included in this report. The company plans to continue to fund its losses from operations and capital funding needs through public or private equity or debt financings, or other sources.

Management Comments

• Management is required to perform a two-step analysis of the Company's ability to continue as a going concern.
• Management's assessment included the preparation of cash flow forecasts resulting in management's conclusion that there is not substantial doubt about the Company's ability to continue as a going concern.

Industry Context

The biopharmaceutical industry is highly competitive, with numerous companies developing cancer therapies. BioAtla's focus on conditionally active biologics (CABs) represents a novel approach, but the company faces competition from established players and emerging technologies. The licensing agreement with Context Therapeutics is a positive step, but the company's long-term success depends on the clinical development and commercialization of its product candidates.

Comparison to Industry Standards

• BioAtla's Q3 2024 results show a significant reduction in net loss compared to the same period in 2023, which is a positive trend compared to many other clinical-stage biotech companies that often experience increasing losses as they progress through clinical trials.
• The $11 million revenue from the Context Therapeutics licensing agreement is a notable achievement for a company that has not previously generated product revenue, and this is a positive sign compared to other companies that rely solely on funding.
• The decrease in R&D expenses is a positive sign of cost management, which is important for biotech companies that are often criticized for high spending. This is a positive trend compared to other companies that often experience increasing R&D expenses as they progress through clinical trials.
• However, BioAtla's cash burn rate remains high, and the company will need to raise additional capital to continue its operations, which is a common challenge for clinical-stage biotech companies.
• Compared to companies like Xencor and MacroGenics, which also focus on antibody-based therapeutics, BioAtla is still in an earlier stage of development and has not yet achieved significant revenue from product sales.
• The company's reliance on third-party manufacturers is also a common practice in the biotech industry, but it introduces risks related to supply chain and quality control, which is a common challenge for many biotech companies.

Related Party Transactions

• In January 2024, the Company entered into an amended Clinical Trial Services Agreement with Himalaya Therapeutics SEZC.
• In September 2024, the Company entered into a Global Transaction Agreement with Himalaya Therapeutics SEZC.
• The company recognized $1.8 million and $2.0 million, respectively, in research and development expense related to the transactions with Himalaya for the three and nine months ended September 30, 2024.

Stakeholder Impact

• Shareholders: The company's improved financial results and licensing agreement are positive developments, but the need for additional capital and the risks associated with drug development remain concerns.
• Employees: The company's growth and development plans may create new opportunities, but the company's financial situation may also create uncertainty.
• Customers: The company's product candidates have the potential to address unmet medical needs, but their development is still in progress.
• Suppliers: The company's reliance on third-party manufacturers creates opportunities for suppliers, but also introduces risks related to supply chain and quality control.
• Creditors: The company's financial situation may create risks for creditors, but the company's improved results and licensing agreement are positive developments.

Next Steps

• Continue clinical development of mecbotamab vedotin, ozuriftamab vedotin, evalstotug, and BA3182.
• Expand the pipeline of bispecific and other CAB antibody-based product candidates.
• Maintain, protect and expand the intellectual property portfolio.
• Seek marketing approvals for product candidates that successfully complete clinical trials.
• Establish additional product collaborations and commercial manufacturing relationships with third parties.
• Build sales, marketing and distribution infrastructure and relationships with third parties to commercialize product candidates.
• Continue to expand operational, financial and management information systems.
• Attract, hire and retain additional clinical, scientific, management, administrative and commercial personnel.

Key Dates

Keywords

BioAtla, CAB, oncology, clinical trials, biopharmaceutical, antibody-drug conjugates, licensing agreement, research and development, financial results, net loss